Palihapitiya Chamath
Palihapitiya Chamath's purchase track record
Palihapitiya Chamath has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/22/2021 | CLOV | $10.00M | -62.4% | -49.4% | -15.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Clover Health Gains After Earning 5-Star CMS Rating. Clover Health stock rose after the company secured a 5-star rating for its PPO plan from CMS for 2027. This top score supports the company's long-term outlook and may help attract new members. The news follows a period where the stock was trading near its 52-week high, reflecting positive market sentiment.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
SPCE: Spire Global chosen by Precursor SPC for hypersonic tracking. Spire Global was selected by Precursor SPC to provide GNSS radio occultation profiles that support hypersonic tracking. The contract is part of a broader effort to improve monitoring of high‑speed vehicles. While the announcement does not involve Virgin Galactic directly, it reflects ongoing developments in aerospace technology that could influence the industry as a whole.
Transaction History
| PROK | ▼ Sell | Open Market | 5,183,367 | $6.8M | 11/19/2023 | View on chart |
| PROK | ▼ Sell | Open Market | 2,073,000 | $2.7M | 11/19/2023 | View on chart |
| PROK | ▼ Sell | Open Market | 258,400 | $308K | 11/17/2023 | View on chart |
| PROK | ▼ Sell | Open Market | 212,100 | $259K | 11/16/2023 | View on chart |
| PROK | ▼ Sell | Open Market | 282,300 | $420K | 11/15/2023 | View on chart |
| PROK | ▼ Sell | Open Market | 306,200 | $459K | 11/14/2023 | View on chart |
| PROK | ▼ Sell | Open Market | 88,700 | $140K | 11/13/2023 | View on chart |
| PROK | ▼ Sell | Open Market | 85,900 | $138K | 11/10/2023 | View on chart |
| PROK | ▼ Sell | Open Market | 95,900 | $161K | 11/9/2023 | View on chart |
| PROK | ▼ Sell | Open Market | 59,000 | $98K | 11/8/2023 | View on chart |
| PROK | ▼ Sell | Open Market | 71,233 | $113K | 11/7/2023 | View on chart |
| PROK | ▼ Sell | Open Market | 79,600 | $124K | 11/6/2023 | View on chart |
| PROK | ▼ Sell | Open Market | 148,300 | $256K | 11/3/2023 | View on chart |
| PROK | ▼ Sell | Open Market | 133,700 | $232K | 11/2/2023 | View on chart |
| PROK | ▼ Sell | Open Market | 123,400 | $200K | 11/1/2023 | View on chart |
| PROK | ▼ Sell | Open Market | 141,900 | $239K | 10/31/2023 | View on chart |
| PROK | ▼ Sell | Open Market | 157,000 | $260K | 10/30/2023 | View on chart |
| PROK | ▼ Sell | Open Market | 92,500 | $147K | 10/27/2023 | View on chart |
| PROK | ▼ Sell | Open Market | 77,960 | $141K | 10/26/2023 | View on chart |
| PROK | ▼ Sell | Open Market | 67,213 | $118K | 10/25/2023 | View on chart |
| PROK | ▼ Sell | Open Market | 176,300 | $309K | 10/24/2023 | View on chart |
| PROK | ▼ Sell | Open Market | 160,300 | $293K | 10/23/2023 | View on chart |
| PROK | ▼ Sell | Open Market | 87,200 | $168K | 10/20/2023 | View on chart |
| PROK | ▼ Sell | Open Market | 200,000 | $439K | 10/19/2023 | View on chart |
| PROK | ▼ Sell | Open Market | 125,100 | $285K | 10/18/2023 | View on chart |
| PROK | ▼ Sell | Open Market | 106,400 | $301K | 10/17/2023 | View on chart |
| PROK | ▼ Sell | Open Market | 215,543 | $619K | 10/16/2023 | View on chart |
| PROK | ▼ Sell | Open Market | 250,000 | $668K | 10/13/2023 | View on chart |
| PROK | ▼ Sell | Open Market | 18,775 | $59K | 10/12/2023 | View on chart |
| PROK | ▼ Sell | Open Market | 143,088 | $377K | 10/12/2023 | View on chart |
| PROK | ▼ Sell | Open Market | 75,000 | $288K | 10/11/2023 | View on chart |
| PROK | ▼ Sell | Open Market | 75,000 | $325K | 10/10/2023 | View on chart |
| PROK | ▼ Sell | Open Market | 75,000 | $315K | 10/9/2023 | View on chart |
| PROK | ▼ Sell | Open Market | 75,000 | $336K | 10/6/2023 | View on chart |
| PROK | ▼ Sell | Open Market | 52,621 | $251K | 10/5/2023 | View on chart |
| PROK | ▼ Sell | Open Market | 1,700,000 | $9.3M | 9/19/2023 | View on chart |
| PROK | ▲ Buy | Option Exercise | 6,220,000 | $0 | 7/11/2022 | View on chart |
| PROK | ▼ Sell | Other | 3,087,000 | $0 | 7/11/2022 | View on chart |
| PROK | ▲ Buy | Grant | 9,000,000 | $90.0M | 7/11/2022 | View on chart |
| CLOV | ▲ Buy | Open Market | 1,739,130 | $10.0M | 11/22/2021 | View on chart |
| SPCE | ▼ Sell | Gift | 125,960 | $0 | 9/16/2021 | View on chart |
| CLOV | ▼ Sell | Other | 750,000 | $0 | 8/20/2021 | View on chart |
| CLOV | ▲ Buy | Option Exercise | 2,245,980 | — | 8/16/2021 | View on chart |
| CLOV | ▼ Sell | Other | 20,500,000 | — | 7/7/2021 | View on chart |
| SPCE | ▼ Sell | Other | 3,492,995 | $40.2M | 3/18/2021 | View on chart |
| SPCE | ▼ Sell | Other | 142,306 | $4.5M | 3/18/2021 | View on chart |
| SPCE | ▼ Sell | Other | 388,111 | $4.5M | 3/18/2021 | View on chart |
| SPCE | ▼ Sell | Other | 1,280,750 | $40.2M | 3/18/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
PROK: Eight ProKidney Abstracts Chosen for Kidney Week 2026
ProKidney Corp. announced that eight of its research abstracts were chosen to be presented at the American Society of Nephrology’s Kidney Week 2026. The selection highlights the company’s active research program in kidney disease. It shows that ProKidney’s work is gaining recognition from the nephrology community. The news may support the company’s long‑term development plans.
PROK: Eight ProKidney Abstracts Chosen for Kidney Week 2026. ProKidney Corp. announced that eight of its research abstracts were chosen to be presented at the American Society of Nephrology’s Kidney Week 2026. The selection highlights the company’s active research program in kidney disease. It shows that ProKidney’s work is gaining recognition from the nephrology community. The news may support the company’s long‑term development plans.